MVI-targeted carbon-ion radiotherapy combined with immunotherapy for advanced hepatocellular carcinoma: Phase Ib DEPARTURE trial

Background & Aims: Advanced hepatocellular carcinoma (HCC) with macrovascular invasion (MVI) carries an extremely poor prognosis, necessitating novel therapeutic strategies. This phase Ib trial evaluated the safety and preliminary efficacy of combining carbon-ion radiotherapy (C-ion RT) with imm...

Description complète

Détails bibliographiques

Auteurs principaux:	Sadahisa Ogasawara, Keisuke Koroki, Hirokazu Makishima, Masaru Wakatsuki, Asahi Takahashi, Makoto Fujiya, Sae Yumita, Miyuki Nakagawa, Hiroaki Kanzaki, Kazufumi Kobayashi, Masanori Inoue, Masato Nakamura, Naoya Kanogawa, Takayuki Kondo, Shingo Nakamoto, Tomoya Kurokawa, Yoshihito Ozawa, Yosuke Inaba, Soumith Paritala, Jingxuan Chen, Jeon Lee, Yujin Hoshida, Hideki Hanaoka, Shigeru Yamada, Hitoshi Ishikawa
Format:	Artigo
Langue:	Inglês
Publié:	Elsevier 2026-05-01
Collection:	JHEP Reports
Sujets:	Carbon-ion radiotherapy Durvalumab Tremelimumab Hepatocellular carcinoma
Accès en ligne:	http://www.sciencedirect.com/science/article/pii/S2589555926000364
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!